
The Economics of Cancer Screening and Services ^{Ciaran O'Neill (PhD)} Professor of Health Economics Queen's University Belfast

• Contents

- Background
 - Mortality
 - Morbidity
 - Cost
- Contributions of economics
 - Evaluation
 - Incentives
 - Prevention
 - Equity
- Final thoughts

Cancer mortality and morbidity

• Now cancer is the second largest source of deaths in the EU (after cardiovascular disease



Source: Eurostat (online data code: hlth_cd_aro)



Cancer is the second largest source of DALYs in the EU (after cardiovascular diseases)

Burden of disease by cause, European Region (WHO), 2019



Total disease burden, measured in Disability-Adjusted Life Years (DALYs) by sub-category of disease or injury. DALYs measure the total burden of disease – both from years of life lost due to premature death and years lived with a disability. One DALY equals one lost year of healthy life.


Cardiovascular diseases			72.15 million
Cancers		49.16 million	
Musculoskeletal disorders	23.12 million		
Mental disorders	17.45 million		
Other NCDs	17.37 million		
Neurological disorders	17.18 million		
Unintentional injuries	16.11 million		
Digestive diseases	13.29 million		
Diabetes and kidney diseases	12.88 million		
Respiratory diseases	10.45 million		
Respiratory infections and TB	7.53 million		
Substance use disorders	7.28 million		
Transport injuries	6.3 million		
Self-harm	5.66 million		
Skin diseases	5.64 million		
Neonatal disorders	4.66 million		
Interpersonal violence	2.27 million		
Nutritional deficiencies			
HIV/AIDS and STIs			
Enteric infections			
Other infectious diseases	880,031.86		
Malaria & neglected tropical diseases	266,149.93		
Maternal disorders	132,241.48		
Conflict and terrorism	127,494.94		
Natural disasters	30,929.76		


Data source: IHME, Global Burden of Disease (2019)

OurWorldInData.org/burden-of-disease | CC BY

Note: Non-communicable diseases are shown in blue; communicable, maternal, neonatal and nutritional diseases in red; injuries in grey. Luxembourg Institute of Health, May 23rd 2024

Health-related quality of life and cancer





Source: Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-Related Quality bourfeline Patients Witht Different Diseases Measured With the EQ-5D-5L: A Systematic Review. Front Public Health. 2021 Jun 29;9:675523. doi: 10.3389/fpubh.2021.675523

The cost of screening and cancer care


- The total cost of cancer was €199 billion in Europe (EU-27 plus Iceland, Norway, Switzerland, and the United Kingdom) in 2018 (Hofmarcher et al., 2020)
- Spending on cancer research has doubled since the mid-1990s, driven by demographic developments and advancements in treating various tumor types
- In 2020, cancer research spending reached €103 billion
- This substantial economic impact underscores the urgency of effective cancer prevention, early detection, and treatment

• There are significant healthcare and non-healthcare costs associated with cancer

Table 1

Total cost of cancer (in million V) in Europe in 2018, by country and component.

Country	Direct costs			Informal care	Indirect costs		Total
	Health expenditure	Share of total	Cancer drugs ^a	costs	Productivity	Productivity	costs
					loss from	loss from	
	on cancer care	health expenditure			premature mortality	morbidity	
Austria	2553	6.4% ^b	952	398	1080	281	4312
Belgium	3240	6.9% ^b	1024	693	1406	1244	6583
Bulgaria	320	7.1% ^b	216	43	174	49	587
Croatia	249	6.8% ^b	149	94	200	427	969
Cyprus	90	6.3%	е	24	40	9	163
Czechia	1084	7.0%	174	192	436	341	2053
Denmark	1499	4.8%	513	764	946	726	3934
Estonia	96	5.8%	5	24	61	75	255
Finland	844	4.0%	331	337	559	154	1895
France	18,707	7.1%	5184	3288	7116	4542	33,652
Germany	25,537	6.8%	7584	5141	11,516	4370	46,564
Greece	942	6.5%	44	314	607	159	2022
Hungary	618	7.1%	388	167	497	91	1372
Iceland	69	3.8%	21	20	44	40	173
Ireland	1139	5.0% ^b	308	180	526	113	1957
Italy	10,374	6.7%	4517	5165	4924	284	20,748
Latvia	111	6.4% ^b	26	33	92	39	274
Lithuania	196	6.4% ^b	55	34	113	82	426
Luxembourg	221	6.9% ^b	7	33	90	37	380
Malta	74	6.5% ^b	е	12	26	2	114
Netherlands	5309	6.9%	1072	982	2485	1387	10,163
Norway	1575	4.2%	366	362	609	666	3212
Poland	2185	7.0%	583	582	1775	784	5327
Portugal	991	5.4%	404	371	655	192	2208
Romania	712	7.1% ^b	351	159	598	160	1629
Slovakia	428	7.1% ^b	166	72	257	173	930
Slovenia	234	6.4%	105	77	166	139	616
Spain	5245	4.9%	2841	2529	3440	950	12,164
Sweden	1907	3.7%	572	491	830	960	4189
Switzerland	4366	6.0%	801	597	1716	477	7157
United Kingdom	11,691	5.0%	3249	3213	6633	1465	23,002
Europe	102,607	6.2%	32,008	26,389	49,615	20,418	199,029



Expenditure per capita in 2018 in Europe (€ per capita PPP-adjusted) Source: Hofmarcher et al (2020)

Notes: Totals of Europe and costs do not match sums of costs because of rounding. No adjustment for price differentials. Cancer drug expenditure do not include confidential rebates. Data on cancer drugs for Cyprus and Malta could not be obtained, and for Estonia, Greece, and Luxembourg they only include retail sales but not hospital sales.

^a Cancer drug expenditure are a subset of the health expenditure on cancer care.

^b Estimated share based on data from similar countries;


Luxembourg Institute of Health, May 23rd 2024

Research spending on cancer

- Increased significantly over time
- Varies by cancer type and country
- Some cancers receive much more research funding than others
- Challenges remain in ensuring equitable funding, effective prevention, and timely detection across all cancers

VARIED INVESTMENT

Research into breast and blood cancers received the most funds between 2016 and 2020, attracting 11% and 9%, respectively, of a total US\$24.5 billion in global cancer-research investment. Cancer biology and drug treatment were the most highly funded research themes, attracting more than 60% of total investment over the five-year period.



*Chart does not include funding for general cancer research and multiple cancer types, which attracted \$7.1 billion and \$2.1 billion, respectively, for 2016-20.

A growing challenge

- Cancer incidence is rising: across Europe it has risen by approximately 50% over the past two decades from 2.1 million to 3.1 million cases (1995-2018)
- In the US the **cost of cancer care is rising** faster than any other health sector (Aksin et al, 2007)
 - Cost-increasing technology (2000-2012 increase in cost to treat each case 4.59%, cancer compared to 4.38%, all diseases in US, Petersen-Kaiser)

• Incidence

- **Population growth and aging:** as people live longer, the risk of developing cancer naturally rises
- Lifestyle factors: poor diet, lack of physical activity, smoking, alcohol consumption contribute to increased cancer risk
- Environmental exposures: exposures to pollutants, radiation and occupational hazards can lead to cancer development
- Improved detection: advances in diagnostic techniques and increased awareness have led to better detection and reporting rates
- Multimorbidity: the median age for the development of multimorbid conditions is 56.94 years

The role of economics in screening and cancer care

- Evaluation: adopt new technologies that are high value and avoid technologies that are low value
- Incentives: payment systems, education and more carefully aligned agency
- **Prevention:** smoking, exercise, screening
- Equity: sources of disparities

Evaluation

Table 1

- Cost-effectiveness analysis <u>can</u> be used to signal price and restrict access (Cherla et al, 2020)
 - Institute for Clinical and Economic Review (US) versus NICE in UK
 - NICE gate-keeps in UK and can negotiate on price
 - Medicare and Medicaid are required to include nearly every FDA approved cancer drug with public formulary – ability to negotiate price reduction much less

Indication Drug		Incremental cost-effectiveness ratio		Recommendation		Concordance of	Reason for Discordance
	_	ICER	NICE	IŒR	NICE	Recommendations	
Non-small Cell Lung Cancer	Atezolizumab (Tecentriq)	\$219,179	< \$71,429	High certainty for benefit despite uncer- tain evidence, exceeds cost-effective- ness (factor of uncertainty)	Recommended with financial agreement	Yes	N/A; not cost-effective in either US or England
	Nivolumab (Opdivo)	\$415,950	\$72,379	High certainty for benefit despite uncer- tain evidence, exceeds cost-effective- ness (factor of uncertainty)	Recommended with a financial and post- market efficacy agreement	Yes	N/A; not cost-effective in either US or England
	Pembrolizumab (Keytruda)	\$236,492	< \$71,429	High certainty for benefit despite uncer- tain evidence, exceeds cost-effective- ness (factor of uncertainty)	Recommended with financial agreement	Yes	N/A; not cost-effective in either US or England
Ovarian, Fallopian, & Peritoneal	Rucaparib (Rubraca)	\$369,175	> \$42,857	Quality adjusted and OS benefit but not priced in alignment with benefit	Recommended with a financial and post- market efficacy agreement	Yes	N/A; not cost-effective in either US or England
Cancer	Niraparib (Zejula)	\$291,454	\$53,804	Quality adjusted and OS benefit, but the price is not aligned with the benefit	Recommended with a financial and post- market efficacy agreement	Yes	N/A; not cost-effective in either US or England
	Olaparib (Lynparza)	\$324,100	> \$42,857	Quality adjusted and OS benefit but not priced in alignment with benefit for platinum sensitive disease	Recommended with a financial and post- market efficacy agreement	Yes	N/A; not cost-effective in either US or England
Multiple Myeloma	Panobinostat (Farydak)	\$10,230	< \$35,765	Promising but concerns over toxicity, long-term cost-effectiveness is uncertain	Recommended with financial agreement	Yes	N/A; cost-effective in both and England
	Ixazomib (Ninlaro)	\$433,794	< \$42,857	Moderate certainty for health benefit, not representative of long-term value at list price	Recommended with a financial and post- market efficacy agreement	No	Higher price in the US
Acute Lymphoblas- tic Leukemia	Tisagenlecleucel (Kymriah)	\$45,871	> \$42,857 - \$64,286	Net health benefit, potentially cost-effec- tive but more evidence for PFS and OS is needed to reduce uncertainty of clin- ical and cost-effectiveness	Recommended with a financial and post- market efficacy agreement	No	Higher cost-effectiveness threshold in the US
ymphoma	Axicabtagene ciloleucel (Yescarta)	\$136,078	> \$71,429	Net health benefit, cost-effective	Recommended with a financial and post- market efficacy agreement	No	Higher cost-effectiveness threshold in the US
Prostate Cancer	Enzalutamide (Xtandi)	\$84,000	\$80,240	High certainty of substantial net health benefit (based on MFS and immature OS data), cost-effective	Not recommended; immature OS evidence not significant, not cost-effective with financial agreement	No	Higher cost-effectiveness threshold in the US, disco dance regarding clinical effectiveness

The NHS ends up paying less for new cancer drugs

Interestingly - the cost per QALY for breast, cervical and colorectal cancer screening has been reported at

\$11.8K-\$29.6K colorectal \$21.8-\$27.6 cervical \$55.2 - \$78.3 breast

Allowing for competing risks (Ratushnyak et al, 2019)

Abbreviations: ICER; Institute for Clinical and Economic Review, NICE; the National Institute for Health and Care Excellence, PFS; progression-free survival, MFS; metastasis-free survival, OS; overall survival. Notes: Drug evaluations from ICER and NICE differ because of their function within the two healthcare systems. In the United Kingdom, NICE makes recommendations for funding decisions in the NHS whereas in the United States, ICEF

does not have a funding mandate and does not make formal decisions for reimbursement. Therefore, the recommendations from the two agencies are distinct and presented differently. 1. For NICE's assessment of atezolizumab the ICER was confidential due to the patient access scheme. NICE explained the ICER was similar to pembrolizumab and likely cost-effective. Less than \$71,429 per QALY was used as an educated

assumption based on the information given.

2. For the assessment of rucaparib, KER used comparators of Pegylated liposomal doxorubicin + carboplatin while NICE used comparators of routine surveillance or olaparit

3. For NICE's assessment of olaparib the base-case ICER was \$42,857 per QALY but this was stated to over value treatment. NICE stated treatment was not a cost-effective use of resources compared with routine surveillance therefore an educated assumption (greater than £30 K per QALY) was used.

4. ICER compared a combination therapy of panobinostat with bortezomb and dexamethasone versus bortezomb and dexamethasone. NICE compared panobinostat with bortezomb and dexamethasone versus lenalidomide and dexamethasone. NICE compared panobinostat with bortezomb and dexamethasone versus lenalidomide and dexamethasone. NICE compared panobinostat with bortezomb and dexamethasone versus lenalidomide and dexamethasone. Site is indicated with lenalidomide and dexamethasone.

6. For tisagenlecleucel, NICE and ICER used different compared to sagenlecleucel to clofarabine while NICE compared it with a composite of salvage chemotherapy as well as blinatumomab, NICE determined that tisagenlecleucel had an incremental cost effectiveness ratio > \$42.857 when compared with salvage chemotherapy and > \$64.286 when compared with blinatumomab.

The role of economics in screening and cancer care

- Evaluation: adopt new technologies that are high value and avoid technologies that are low value
- Incentives: payment systems, education and more carefully aligned agency
- Prevention: smoking, exercise, screening
- Equity: sources of disparities

• Market based reforms

Demand side measures

- Reference based pricing
- Deductibles, co-pays, coinsurance

choke demand

• Supply side measures

• Through information and integration – wide variations in prices for procedures and in practice (Laviana et al, 2020)

Alternatives to low value active treatment

 Palliative care – significantly lower costs in last year of life for hospice versus non-hospice patients \$62,819 versus \$71,517 (Obermeyer et al, 2014) supported by more recent studies (Hoverman et al, 2020)

• Policy environment

- Government guidelines and incentives
- Reimbursement policies
- Legal frameworks


The role of economics in screening and cancer care

- Evaluation: adopt new technologies that are high value and avoid technologies that are low value
- Incentives: payment systems, education and more carefully aligned agency
- **Prevention:** smoking, exercise, screening
- Equity: sources of disparities

Understanding cancer means understanding its relationships with other conditions

Cancer survival by presence of heart condition prior to diagnosis: All cancers (ex

NMSC) diagnosed 2011-2014



O'Neill et al. BMC Cancer (2022) 22:847 https://doi.org/10.1186/s12885-022-09944-z **BMC** Cancer

RESEARCH



Survival of cancer patients with pre-existing heart disease

Ciaran O'Neill^{1,2*}, David W. Donnelly¹, Mark Harbinson³, Therese Kearney², Colin R. Fox¹, Gerard Walls^{4,5} and Anna Gavin¹

Abstract

Background: While cancer outcomes have improved over time, in Northern Ireland they continue to lag behind those of many other developed economies. The role of comorbid conditions has been suggested as a potential contributory factor in this but issues of data comparability across jurisdictions has inhibited efforts to explore relationships. We use data from a single jurisdiction of the UK using data from - the Northern Ireland Cancer Registry (NICR), to examine the association between mortality (all-cause and cancer specific) and pre-existing cardiovascular diseases among patients with cancer.

Materials and Methods: All patients diagnosed with cancer (excluding non-melanoma skin cancer) between 2011 and 2014 were identified from Registry records. Those with a pre-existing diagnosis of cardiovascular diseases were identified by record linkage with patient hospital discharge data using ICD10 codes. Survival following diagnosis was examined using descriptive statistics and Cox proportional hazards regression analyses. Analyses examined all-cause mortality and cancer specific mortality for lung, colorectal, breast and prostate cancer. As well as cardiovascular diseases, regression models controlled for age, gender (where appropriate), deprivation (as quintiles), stage at diagnosis and other comorbidities.

Results: Almost 35,000 incident cancer cases were diagnosed during the study period of which approximately 23% had a prior heart condition. The pan-cancer hazard ratio for death in the presence of pre-existing cardiovascular diseases was 1.28 (95% CI: 1.18-1.40). All-cause and cancer specific mortality was higher for patients with cardiovascular diseases across lung, female breast, prostate and colorectal cancer groups after controlling for age, gender (where appropriate), deprivation (as quintiles), stage at diagnosis and other comorbidities.

Conclusion: Pre-existing morbidity may restrict the treatment of cancer for many patients. In this cohort, cancer patients with pre-existing cardiovascular diseases had poorer outcomes than those without cardiovascular diseases. A high prevalence of cardiovascular diseases may contribute to poorer cancer outcomes at a national level.

Keywords: survival, cancer, pre-existing cardiovascular disease

Similar patterns for lung, colorectal, female breast cancer and prostate cancer

Pre-existing CVD effects treatment and cost Emergent CVD (toxicity) effects costs and outcomes

The role of economics in screening and cancer care

- Evaluation: adopt new technologies that are high value and avoid technologies that are low value
- Incentives: payment systems, education and more carefully aligned agency
- **Prevention:** smoking, exercise, screening
- Equity: sources of disparities

Inequalities in cancer (screening)





Fig. 1. Adjusted odds ratios and 95% confidence intervals of having mammography more than two years ago and within the past two years (multivariate analysis). Fig. 1. Adjusted odds ratios and 95% confidence intervals of having mammography more than two years ago and within the past two years (multivariate analysis). an

Fig. 2. Adjusted odds ratios and 95% confidence intervals of having a cervical smear test more than three years ago and within the past three years (multivariate analysis). The base category is "never screened".

Fig. 3. Adjusted odds ratios and 95% confidence intervals of being up-to date with colorectal cancer testing (having a FOB-test within the past 2 years or colonoscopy within the past 10 years) or being not up-to date (having a FOB-test more than 2 years ago or colonoscopy more than 10 years ago) (multivariate analysis). The base category is "never screened".

Source: Bozar et al 2022, Socio-economic inequality of utilization of cancer testing in Europe A cross sectional studyPrev Med Rep. 2022 Feb 8;26:101733. doi: 10.1016/j.pmedr.2022.101733. PMID: 35198362;

Inequalities in cancer (outcomes)



Source: Varcarella et al, 2022. Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study Lancet Reg Health Eur. 2022 Nov 28;25:100551. doi: 10.1016/j.lanepe.2022.100551.

	⊕ pd/sciencel / 1+2,0-\$11688100025K-main ~	Gews 🗅 Travel 🔟 Institutional Login 📀 New Tab 📔 Sign in 🚺 Portal - Gateway 📀 Surveys - Eurobaro 📀 Adobe Acrobat	Health services generarch Tencie Research
SES has a	Health Palar #120111388-275	Health Economics	The ole of private care in the interval between diagnosis and
role in	Contents lies available at ScienceDirect	Health Economics Letter 🙆 Full Access	And a detail of breast cancer in Northern Ireland: an analysis of Registry data detail details for the formed former Other I
	Health Policy	THE ROLE OF PRIVATE MEDICAL INSURANCE IN SOCIO- ECONOMIC INEQUALITIES IN CANCER SCREENING UPTAKE IN	Elip Patricia Camey ¹ , Anna Gavin ² , Caran O'Nell ¹ Tari Conspondence to Parlessor Clean O'Nell Clean onell'Anagolegy in
<pre>screening /</pre>		IRELAND Brendan Walsh. Mary Silles, Ciaran O'Nelli	Abstract Objective To examine the differences in the interval between diagnosis and initiation of treatment among women with breast
uptake	The importance of socio-economic variables in cancer screening participation: A comparison between population-based and	First published: 09 September 2011 https://doi.org/10.1002/hec.1784 Citations: 33 Full Text	Cancer in Northern Ireland. Repol Report Report Report Design A cross-sectional study.
	opportunistic screening in the EU-15 Breman Walsh, Mary Silles, Ciarán O'Neill*	IIII SECTIONS 🔀 PDF 🍾 TOOLS < SHARE	And And Participants All women diagnosed and treated for breast cancer in Northern Ireland in 2006.
	School of Bauers and Ensuresity, National Distoresty of Printing Galong, Indiand A R I C L E I N F O A R 5 T R A C T	SUMMARY	metrics Main outcome measure The number of days between diagnosis and initiation of treatment for breast cancer.
As does	Rywold: Objective: To investigate differences in participation with breast and cervical cancer screen- socio-penemic in plane in individual socio-economic characteristics anose nonlation-based versus	Screening is seen by many as a key element in cancer control strategies. Differences in uptake of screening related to socio-economic status exist and may contribute to	Arrow the mean (median) interval between diagnosis and initiation of treatment among public patients was 191(15) compared with 14 (12) among those whose care involved private providers. The differences between individial public providers were as marked as those between the public and private sector—the mean indicatal anging between 14 (12) and 25 (22) days.
<pre>ethnicity</pre>	Hindow Inpute Abert sensing Methodic birar from Cambraneter 66.2 "Neath in the European Union" 2006 on self- Marine party Constances Constances which the Statistical Constance (Statistical Constance) which the Statistical Constance (Statistical Constance) based on the screening with includency. (Moreover, Statistical Constance) Statistical Constances Statistical	differences in morbidity and mortality across socio-economic groups. Although a number of factors are likely to underlie differential uptake, differential access to subsequent	Multivariate models revealed that the differences were evident when a range of patient characteristics were controlled for including cancer stage.
centrelety	respectively for breast and cervical cancer screening were available. Duta on maintal area- ton, self-reported backh, occursconning roups and parts of detacation were also available. Screening programmes were categorised as populator-based or opportunitic and logi- fic serversion analysis used to reason the back and the maintain individual	diagnostic tests and/or treatment may have a pivotal role. This study examines differences in the uptake of cancer screening in Ireland related to socio-economic status. Data were extracted from SLÁN 2007 concerning uptake of breast, cervical, colorectal	Conclusions A relatively small number of women received care privately in Northern Ireland but experienced shorter intervals. Detween diagnosis and initiation of treatment than those who exceived care wholly in the public system. The variation among
	characteristics and programme type. Results: Differences in participation related to socio-economic status were observed in opportunistics screening programmes for breast cancer (08-0.637 and 08-0.517 million) enviral cancer (08-0.577 million) (08-0.6577) Differences related to socio-economic charac-	and prostate cancer screening in the preceding 12 months. Concentration indices were calculated and decomposed. Particular emphasis was placed in the decomposition upon the impact of private health insurance, evidenced in other work to impact on access to	oblic providers was as great at that between the public and private providers. The pract of such differences on survival and in sight - waking time targets introduced in Northern feland warrants investigation. This is an New Access anticle distribution accordance with the create Common Attribution Non Commercial ICC BYNC3.0
(Insurance)	teristics were not found with respect to participation in population-based programmes. Conclusions in opportunistic programmes, differences in participation across socio- economic groups are revident in respect to thoth thesat and cervical cance screening. These differences may have implications for transmers and contomics across socio-econogie	Size within the mixed public-private Irish health system. This study found that significant differences related to socio-economic status exist with respect to uptake of pricer screening, with that the main determinant of difference for breast, coloredia and prostate	license, which pennis others to distribute, remit, adapt, build upon this work non-commercially, and license their deniated works on different terms, provided the original work is properly cited and the use is non-commercial. See:
	grups. Such differences were not evident in population-based programmes. © 2011 Elsevier Iteratud Int. All right-spectred.	subterning and that the main betterninianit or uniference to bready, conjectual and prostate cancer screaning the processes of orbitate incursance. This membra profound	http://creativecommons.org/Texcept/bync/3.0/
/Health	SEC A 11.441 In the Department Review Device	Sage Journals International Transmission	
preferences		And Harris Taken & Margin Second State (1999)	⊜_j_serior / H2852303.300560 eals - Q (C) ± ⊕
prererences	Socioeconomic Disparifies Across Ethnicities	Sime 12 and Calculate Data Calculate	horistics Bachter Royan 24 (2021) 102514
	An Application to Constal Cancer Screening Other # 201 Enter Bith RD Cancer Bith RD	© Organization Research P Prostate cancer screening practices in the Republic of Ireland	Contemition unable of SourceContext Preventive Medicine Reports Preventive Medicine Re
	Allow KN The based and of Meager Gas Separate 201 Variant 21 Ison 2	The determinants of uptake Richal Brass. Rendan Wahh Liads Share, and Curra O'well	E.S.Nike journal tempsage www.shaver.com/scategories Reports
Private care	A secondulation of evaluations with the evaluation of a second se	Objectives: The objectives of the appear are to analyze the dominant of prostnet cancer accessing spatie in the Republic of Lindania and to compare the topic of non-need flavors a spatie of coroning	Health preferences and preventive care utilisation: How EQ-SD-SL health preferences may affect uptake
	Assistant, I Objective Our am is to investigate subsectoremit disparities in certair cancer surveying satisfation among and between entity appears in the located taken.	quark in an approximation and an according to a second sec	Dan Kelleher ^{4,2} , Edd Doherty ^{4,2} , Garan O'Nelll ^{1,2} "attatist knows at <i>Nato</i> studies care, broad "interface doings pixed "assort built kindl, and a studies pixed had.
has a role in	Shedy Design Charvariansi mady. Mathada Cha an 20,33 annan agat 21 to 64 para wew	accome-chand concernation and/or and decomposition of the nulces using data collected as part of the Surray of Lindong ten ad Marcania (SLAN) 2007. Comparisons were and a zones prosp all-metration by an it forms of the expected studie of the proton encourses and and the studies of the studies of the distribution of the studies of the studies of the studies of the studies of the studies of the studies of the studies of the	ASTICLEINTO ASSISTACT Report: Depice for emanatic and built heading of generative care being und exalabled, the quale of any non-
interval	Methodus Costa and Land Samanna Agent 21 to da para wave occiaed and the 2020 To 2511 to 2511 space that the Medical Expenditure Panel Sourcey. Data on central cancer streeting calibration in the panelogical Calibration and Januar and a range of costoriary paties of calobiation and panels and a range	Results: Update of grounds coming in name 40 years and not us in the procedual to another use approximately 20%. Update was higher among these in a per proop that are protected to resort a most beautif throw a Pontent Specific Another (PAS) are based on the folding of the EMSA that Science ap-	Levents by the formands and a back handle of provincing and provincing and a back handle of the provincing of the provin
between	were understate for all normal and across and across solutionic grouping by which loads. Header, and show that solution of the	a bighter in the vert higher in the vert higher is observed in the vert of the performance in the vert higher is observed in the vert of the performance in the vert higher is observed in thigher is ob	Voltak Politikan Berlinder Steiner Berlinder Steiner Berlinde
	examine undersition in undersition indexed to accomposition feature and which projects controlling for a range of particular characterizities	among those gets 55.40 (and a means a significant determinant for those appel 41.54 (20%) and those appel 70 and news (21%) Constraints. There are high levels of prostner cancer scoreining uprate and significant incomes found	ingelihood decisionation of all the presence outworks that a contrading the other strends discover that for higher is subsidiary and the streng has been perfected by even in the other strends and the discover discover discover discover discover discover discover discover discover discover discover weeking to instrue demand edu lection for promotive care update.
diagnosis	Results: Avrual stituation nine are high in the United Educes (60.15%) and gravitate arrange labol services (36.5%). Disputities, air mean-red by momentation indices (30), are burgen the United Educes, with the stight body for white	aseguida na supetita di na di anzia difficiale di anzia di anzia di anzia di anzia di anzia di forma encore alvona overali na di anzia differenti age progra ne na bubijer el dobte, nel habe dei esperaga mi income estanti anqualities au quales varanti closer attentos and siemficatione el podenti policy reprotores.	I. hereduction if presentire care is associated with how look of efforts in the distance on the analysis of the distance of the distance on the distance of the dista
and	venners (C. 6.178) etidade to Listed (C. 8.178) etid Hispanic (C. High, News ajoc.com/etiolobioscom/o drageties aurose etinades auros etinades aurose etinades auros etinades aurose etinades auro	Luxembourg Institute of Health, May 23rd 2024	design public factors in explaining the upsiles of perventice are ser- tions of M_{2} (Section 2014). The section 2014 of M_{2} (Section 2014) where the factor is and M_{2} (Section 2014) where the factor is an effective factor is an effective factor in the factor in the factor is an effective factor in the factor in the factor is an effective factor in the factor in the factor is an effective factor in the factor in the factor is an effective factor in the factor in the factor is an effective factor in the factor in the factor is an effective factor in the factor in the factor is an effective factor in the factor is an effective factor in the factor in th
treatment			

PDF

Inequalities in experience of financial toxicity (objective financial burden and subjective financial distress that can attend a cancer diagnosis and treatment) Zafar et al, 2013

• More evident in US than UK

•

- More evident among those with lower income
- More evident among those of working age

- Final thoughts
 - Cancer presents many challenges
 - Economics can help inform our responses
 - There is reason to be concerned
 - There is also reason to be hopeful
 - Survival is improving
 - Rising costs are not immutable
 - Widening inequalities are not immutable

Joyce et al, 2019

References Akscin J, Barr TR, Towle EL: Key practice indicators in office-based oncology practices: 2007 report on 2006 data. J Oncol Pract 3:200-203, 2007

Cherla A, Renwick M, Jha A, Mossialos E. Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England. EClinicalMedicine. 2020 Nov 5;29-30:100625. doi: 10.1016/j.eclinm.2020.100625. PMID: 33437948; PMCID: PMC7788430

Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis. EClinicalMedicine. 2023 Feb 16;57:101860. doi: 10.1016/j.eclinm.2023.101860. PMID: 36864977; PMCID: PMC9971315.

Hoverman JR, Mann BB, Phu S, Nelson P, Hayes JE, Taniguchi CB, Neubauer MA. Hospice or Hospital: The Costs of Dying of Cancer in the Oncology Care Model. Palliat Med Rep. 2020 Jun 25;1(1):92-96. doi: 10.1089/pmr.2020.0023. PMID: 34223463; PMCID: PMC8241329.

Joyce DP, O'Neill C, Heneghan HM, Curran C, Barry K, Sweeney K, Malone C, McLaughlin R, Kerin MJ. The changing cost of breast cancer care: lessons from

a centralised modern cancer centre. Ir J Med Sci. 2019 May;188(2):409-414. doi: 10.1007/s11845-018-1872-4. Epub 2018 Jul 21. PMID: 30032478.

Laviana AA, Luckenbaugh AN, Resnick MJ. Trends in the Cost of Cancer Care: Beyond Drugs. J Clin Oncol. 2020 Feb 1;38(4):316-322. doi: 10.1200/JCO.19.01963. Epub 2019 Dec 5. PMID: 31804864; PMCID: PMC6994251.

Nikitara K, Odani S, Demenagas N, Rachiotis G, Symvoulakis E, Vardavas C. Prevalence and correlates of physical inactivity in adults across 28 European countries. Eur J Public Health. 2021 Oct 11;31(4):840-845. doi: 10.1093/eurpub/ckab067. PMID: 34000007; PMCID: PMC8504996.

Obermeyer Z, Makar M, Abujaber S, et al: Association between the Medicare hospice benefit and health care utilization and costs for patients with poorprognosis cancer. JAMA 312:1888-1896, 2014

Peterson-Kaiser Health System Tracker: What are recent trends in cancer spending and outcomes? https://www.healthsystemtracker.org/chart-collection/ recent-trends-cancer-spending-outcomes/#item-u-s-higher-average-disease-burden-lung-cancer

Pineda E, Sanchez-Romero LM, Brown M, Jaccard A, Jewell J, Galea G, Webber L, Breda J. Forecasting Future Trends in Obesity across Europe: The Value of Improving Surveillance. Obes Facts. 2018;11(5):360-371. doi: 10.1159/000492115. Epub 2018 Oct 12. PMID: 30308509; PMCID: PMC6257099.

Ratushnyak S, Hoogendoorn M, van Baal PHM. Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained. Am J Prev Med. 2019 Dec;57(6):792-799. doi: 10.1016/j.amepre.2019.07.027. PMID: 31753260

Woods L, Slotkin JR, Coleman MR: How employers are fixing health care. Harvard Business Review. https://hbr.org/cover-story/2019/03/how-employers-arefixing-health-care. Accessed 14 May 2024

Zafar SY, Abernethy AP. Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park). 2013;27(2):80-149. Luxembourg Institute of Health, May 23rd 2024

Thank you!

Any questions